This is in agreement with Dales et al. [31] who showed that VEGFR1 protein expression identified BC patients with a worse outcome, and suggested its use for evaluating tumor aggressiveness in order to select the best therapeutic approach. The gene discussed is FLT1; the disease is neoplasm.